Skye shareholders approve acquisition of Emerald Health; Phase 1 trial imminent

Skye Bioscience, Inc.

97% of votes cast (excluding affiliates) approved the acquisition of Emerald Health Therapeutics.
Expected closing before October 15, subject to Canadian Securities Exchange listing approval.
Phase 1 trial of SBI-100 in glaucoma to start in Australia; first dosing expected in November 2022.
Final manufacturing step is quality testing; drug product expected to be available in October 2022.
Auditor changed from Friedman LLP to Marcum LLP following merger; no disagreements reported.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.